Combating COVID-19: The role of drug repurposing and medicinal plants
Shah Alam Khan,K. Al-Balushi +1 more
TLDR
The aim of this mini-review is to give an overview of identified repurposed anti-COVID-19 drugs which are currently under clinical trials and explore antiviral medicinal plants as adjunct or supportive therapy.About:
This article is published in Journal of Infection and Public Health.The article was published on 2021-04-01 and is currently open access. It has received 40 citations till now. The article focuses on the topics: Literature survey & Drug repositioning.read more
Citations
More filters
Journal ArticleDOI
Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19.
Mohd. Imran,Mandeep Kumar Arora,Syed Mohammed Basheeruddin Asdaq,Shah Alam Khan,Saleh I. Alaqel,Mohammed Kanan Alshammari,Mohammed M. Alshehri,Ahmed Subeh Alshrari,Alreshidi Mateq Ali,Ahmed Muteb Al-Shammeri,Bushra Dhuhayyan Alhazmi,Aishah Ali Harshan,Tauquir Alam +12 more
TL;DR: Molnupiravir as mentioned in this paper, an orally active RdRp inhibitor, is in a phase 3 clinical trial against COVID-19 and has shown good safety profile, tolerability, and oral bioavailability in humans.
Journal ArticleDOI
Recent advances on drug development and emerging therapeutic agents for Alzheimer's disease.
TL;DR: A brief review article is intended to cover the recent advances in drug development and emerging therapeutic agents for Alzheimer's disease acting at different targets as discussed by the authors, which is concluded that novel therapeutic strategies are required to discover and develop therapeutic agents to fight against the century old AD.
Journal ArticleDOI
Use of medicinal plants for COVID-19 prevention and respiratory symptom treatment during the pandemic in Cusco, Peru: A cross-sectional survey.
Magaly Villena-Tejada,Ingrid Vera-Ferchau,Anahí Cardona-Rivero,Rina Zamalloa-Cornejo,Mercedes Maritza Quispe-Flórez,Zany Frisancho-Triveno,Rosario C Abarca-Melendez,Susan G Alvarez-Sucari,Christian R. Mejia,Jaime A. Yáñez +9 more
TL;DR: In this article, a web-based cross-sectional study was conducted on general public (20-to 70-year-old) from August 31 to September 20, 2020.
Journal ArticleDOI
The find of COVID-19 vaccine: Challenges and opportunities
Marwan ElBagoury,Mahmoud M. Tolba,Hebatallah A. Nasser,Abdul Jabbar,Ahmed M. Elagouz,Yahia Aktham,Amy Hutchinson +6 more
TL;DR: Wang et al. as mentioned in this paper presented a comprehensive visualization about SARS-CoV-2 to tackle the current pandemic and concluded that vaccines formulation within exceptional no time in this pandemic is highly recommended.
Peer ReviewDOI
A Comprehensive Review of Drug Repurposing Strategies against Known Drug Targets of COVID-19
TL;DR: This review attempts to collate both the experimental and computational drug repurposing strategies that have been utilized against significant drug targets of SARS-CoV-2 and the available druggable targets shall also be discussed.
References
More filters
Journal ArticleDOI
Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission
TL;DR: Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Shanghai 200031, China; Key Laboratory of Synthetic Biology, CAS Center for Excellence in Molecular Plant Sciences, Chinese academy of sciences, Shanghai200032, China.
Journal ArticleDOI
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
TL;DR: Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection able to effect ~5000-fold reduction in viral RNA at 48 h.
Journal ArticleDOI
Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.
Chung-Ming Chu,V C C Cheng,Ivan Hung,M M L Wong,K H Chan,K S Chan,Richard Y.T. Kao,Leo L.M. Poon,C L P Wong,Yi Guan,Joseph S. M. Peiris,Kwok-Yung Yuen +11 more
TL;DR: The apparent favourable clinical response with lopinavir/ritonavir and ribavirin supports further randomised placebo controlled trials in patients with SARS and shows that age, hepatitis B carrier status, and lack of treatment with this antiviral combination were independent predictors of an adverse outcome.
Journal ArticleDOI
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV.
Timothy P. Sheahan,Amy C. Sims,Sarah R. Leist,Alexandra Schäfer,John J. Won,Ariane J. Brown,Stephanie A. Montgomery,Alison Hogg,Darius Babusis,Michael O'neil Hanrahan Clarke,Jamie E. Spahn,Bauer Laura Elizabeth,Scott P. Sellers,Danielle P. Porter,Joy Y. Feng,Tomas Cihlar,Robert Jordan,Mark R. Denison,Ralph S. Baric +18 more
TL;DR: Remdesivir (RDV) has superior anti-MERS activity in vitro and in vivo compared to combination therapy with lopinavir, ritonavir and interferon beta and reduces severe lung pathology.
Journal ArticleDOI
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
TL;DR: This article summarizes agents with potential efficacy against SARS-CoV-2 and indicates some promising results have been achieved thus far.